Enalapril-associated erythema and vasculitis.
Our pharmacologic armamentarium is expanding at a tremendous pace, and requires that we as clinicians maintain a certain level of knowledge of the drugs that we use, as well as their metabolism, and how they may function, both positively and negatively, in a given patient. Certain drugs, such as the angiotensin-converting enzyme inhibitors, interfere with the natural deactivation of certain vasoactive substances normally present in the body. Since many of these systems are functionally interrelated (eg, angiotensin-converting enzyme and kininase II), we may see cutaneous side effects when these drugs are administered. Enalapril is an angiotensin-converting enzyme inhibitor that promoted a cutaneous eruption in a patient with renal failure secondary to diabetes. We suspect that our patient's vasculitis and maculopapular erythema is included in a large number of polymorphic eruptions that can be seen with angiotensin-converting enzyme inhibitors, and review the operative pathogenetic mechanism. Many of these side effects are dose related, and can be controlled or eliminated by lowering the dosage of angiotensin-converting enzyme inhibitor, depending upon the clinical circumstances.
Carrington
P R
PR
Department of Dermatology, Louisiana State University School of Medicine, Shreveport 71130-3932.
Sanusi
I D
ID
Zahradka
S
S
Winder
P R
PR
D000328:Adult; D003875:Drug Eruptions / Q000209:etiology / Q000473:pathology*; D004656:Enalapril / Q000009:adverse effects*; D004890:Erythema / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D006801:Humans; D012867:Skin / Q000098:blood supply / Q000473:pathology; D014657:Vasculitis / Q000139:chemically induced* / Q000473:pathology
D004656:Enalapril